Englitazone
Englitazone
Englitazone (pronounced en-gli-ta-zone) is a thiazolidinedione derivative, which was studied for potential use in the treatment of type 2 diabetes. It is part of the glitazone class of drugs, which function by reducing insulin resistance in the body.
Etymology
The term "Englitazone" is derived from the class of drugs it belongs to, the glitazones, with the prefix "Engli-" being a unique identifier. The "-azone" suffix is common among drugs in this class.
Pharmacology
Englitazone works by binding to the peroxisome proliferator-activated receptors (PPARs), specifically the PPARγ subtype. This binding action activates the receptor, which in turn regulates the transcription of specific genes. This process helps to improve insulin sensitivity in the body, making it a potential treatment for type 2 diabetes.
Development and Status
Englitazone was developed by Eli Lilly and Company, a pharmaceutical company based in the United States. However, it did not progress beyond early-stage clinical trials due to its relatively weak potency compared to other drugs in the same class, such as pioglitazone and rosiglitazone.
Related Terms
- Thiazolidinedione: A class of drugs that reduce insulin resistance in the body.
- Glitazone: A subclass of thiazolidinediones, which includes drugs like englitazone, pioglitazone, and rosiglitazone.
- Peroxisome proliferator-activated receptors (PPARs): A group of nuclear receptor proteins that function to regulate the expression of genes.
- Type 2 diabetes: A chronic condition that affects the way the body processes blood sugar (glucose).
External links
- Medical encyclopedia article on Englitazone
- Wikipedia's article - Englitazone
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski